Both for stroke/SE and stroke/SE/cardiovascular death, the risk reduction for ILR screening compared with usual care appeared to increase with higher NT-proBNP levels, and the trend curves crossed the reference line (HR = 1) at an NT-proBNP level of 9 pmol/L. This evidence concerns the gene NPPB and stroke disorder.